{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T22:45:57Z","timestamp":1782600357731,"version":"3.54.5"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010896","name":"International Cooperation and Exchange Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010896","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002822","name":"Central South University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002822","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.bcp.2019.06.014","type":"journal-article","created":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T11:02:38Z","timestamp":1560510158000},"page":"14-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["CX-F9, a novel RSK2 inhibitor, suppresses cutaneous melanoma cells proliferation and metastasis through regulating autophagy"],"prefix":"10.1016","volume":"168","author":[{"given":"Xu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisha","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JiangLing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianda","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8187-636X","authenticated-orcid":false,"given":"Cong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bcp.2019.06.014_b0005","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc.2016.37","article-title":"From melanocytes to melanomas","volume":"16","author":"Shain","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"10.1016\/j.bcp.2019.06.014_b0010","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1242\/dev.123729","article-title":"The melanocyte lineage in development and disease","volume":"142","author":"Mort","year":"2015","journal-title":"Development"},{"issue":"2","key":"10.1016\/j.bcp.2019.06.014_b0015","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejcsup.2013.07.012","article-title":"Melanoma epidemiology, biology and prognosis","volume":"11","author":"Ali","year":"2013","journal-title":"EJC Suppl."},{"issue":"4","key":"10.1016\/j.bcp.2019.06.014_b0020","first-page":"215","article-title":"Malignant melanoma: prevention, early detection, and treatment in the 21st century","volume":"50","author":"Rigel","year":"2000","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.bcp.2019.06.014_b0025","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/bjd.15510","article-title":"The global burden of melanoma: results from the Global Burden of Disease Study 2015","volume":"177","author":"Karimkhani","year":"2017","journal-title":"Br. J. Dermatol."},{"issue":"5","key":"10.1016\/j.bcp.2019.06.014_b0030","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2019.06.014_b0035","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.critrevonc.2009.08.005","article-title":"Treatment for metastatic malignant melanoma: old drugs and new strategies","volume":"74","author":"Mouawad","year":"2010","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"5","key":"10.1016\/j.bcp.2019.06.014_b0040","doi-asserted-by":"crossref","first-page":"8069","DOI":"10.18632\/oncotarget.14094","article-title":"Heterogeneity and frequency of BRAF mutations in primary melanoma: comparison between molecular methods and immunohistochemistry","volume":"8","author":"Bruno","year":"2017","journal-title":"Oncotarget."},{"issue":"3","key":"10.1016\/j.bcp.2019.06.014_b0045","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.3892\/ol.2017.6608","article-title":"Mutations in BRAF codons 594 and 596 predict good prognosis in melanoma","volume":"14","author":"Wu","year":"2017","journal-title":"Oncol Lett."},{"issue":"4","key":"10.1016\/j.bcp.2019.06.014_b0050","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/bjd.15829","article-title":"The evolving universe of BRAF mutations in melanoma","volume":"177","author":"Schaider","year":"2017","journal-title":"Br. J. Dermatol."},{"issue":"5","key":"10.1016\/j.bcp.2019.06.014_b0055","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/pcmr.12123","article-title":"KIT, NRAS, and BRAF mutations in nail apparatus melanoma","volume":"26","author":"Dika","year":"2013","journal-title":"Pigm. Cell Melanoma Res."},{"issue":"2","key":"10.1016\/j.bcp.2019.06.014_b0060","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s12032-016-0879-9","article-title":"KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma","volume":"34","author":"Cicenas","year":"2017","journal-title":"Med. Oncol."},{"issue":"2","key":"10.1016\/j.bcp.2019.06.014_b0065","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2310\/7750.2011.11064","article-title":"KIT gene mutations and patterns of protein expression in mucosal and acral melanoma","volume":"16","author":"Abu-Abed","year":"2012","journal-title":"J. Cutaneous Med. Surg."},{"issue":"6","key":"10.1016\/j.bcp.2019.06.014_b0070","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamadermatol.2013.8442","article-title":"Dark homogeneous streak dermoscopic pattern correlating with specific KIT mutations in melanoma","volume":"150","author":"Sanchez","year":"2014","journal-title":"JAMA Dermatol."},{"issue":"3","key":"10.1016\/j.bcp.2019.06.014_b0075","doi-asserted-by":"crossref","first-page":"135","DOI":"10.18632\/oncotarget.240","article-title":"Ras\/Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health","volume":"2","author":"Chappell","year":"2011","journal-title":"Oncotarget"},{"issue":"40","key":"10.1016\/j.bcp.2019.06.014_b0080","doi-asserted-by":"crossref","first-page":"64778","DOI":"10.18632\/oncotarget.11415","article-title":"CD147 silencing inhibits tumor growth by suppressing glucose transport in melanoma","volume":"7","author":"Su","year":"2016","journal-title":"Oncotarget"},{"issue":"42","key":"10.1016\/j.bcp.2019.06.014_b0085","doi-asserted-by":"crossref","first-page":"68314","DOI":"10.18632\/oncotarget.11599","article-title":"Propranolol induced G0\/G1\/S phase arrest and apoptosis in melanoma cells via AKT\/MAPK pathway","volume":"7","author":"Zhou","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.bcp.2019.06.014_b0090","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s12272-016-0880-z","article-title":"RSK2 and its binding partners in cell proliferation, transformation and cancer development","volume":"40","author":"Cho","year":"2017","journal-title":"Arch. Pharm. Res."},{"issue":"3","key":"10.1016\/j.bcp.2019.06.014_b0095","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1172\/JCI200522877","article-title":"Essential role of RSK2 in c-Fos-dependent osteosarcoma development","volume":"115","author":"David","year":"2005","journal-title":"J. Clin. Invest."},{"issue":"9","key":"10.1016\/j.bcp.2019.06.014_b0100","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1158\/0008-5472.CAN-04-3935","article-title":"The p53 protein is a novel substrate of ribosomal S6 kinase 2 and a critical intermediary for ribosomal S6 kinase 2 and histone H3 interaction","volume":"65","author":"Cho","year":"2005","journal-title":"Cancer Res."},{"issue":"45","key":"10.1016\/j.bcp.2019.06.014_b0105","doi-asserted-by":"crossref","first-page":"32528","DOI":"10.1074\/jbc.M113.500561","article-title":"The prometastatic ribosomal S6 kinase 2-cAMP response element-binding protein (RSK2-CREB) signaling pathway up-regulates the actin-binding protein fascin-1 to promote tumor metastasis","volume":"288","author":"Li","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.bcp.2019.06.014_b0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074334","article-title":"Ribosomal S6 Kinase 2 (RSK2) maintains genomic stability by activating the Atm\/p53-dependent DNA damage pathway","volume":"8","author":"Lim","year":"2013","journal-title":"PLoS ONE"},{"issue":"11","key":"10.1016\/j.bcp.2019.06.014_b0115","doi-asserted-by":"crossref","first-page":"8380","DOI":"10.1074\/jbc.M611322200","article-title":"RSK2 mediates muscle cell differentiation through regulation of NFAT3","volume":"282","author":"Cho","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.bcp.2019.06.014_b0120","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/carcin\/bgs271","article-title":"RSK2 as a key regulator in human skin cancer","volume":"33","author":"Cho","year":"2012","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bcp.2019.06.014_b0125","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3389\/fonc.2013.00201","article-title":"A rising cancer prevention target of RSK2 in human skin cancer","volume":"3","author":"Arul","year":"2013","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.bcp.2019.06.014_b0130","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1158\/1940-6207.CAPR-12-0425","article-title":"Direct targeting of MEK1\/2 and RSK2 by silybin induces cell-cycle arrest and inhibits melanoma cell growth","volume":"6","author":"Lee","year":"2013","journal-title":"Cancer Prev. Res. (Phila)."},{"issue":"9","key":"10.1016\/j.bcp.2019.06.014_b0135","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/1940-6207.CAPR-14-0126","article-title":"Kaempferol targets RSK2 and MSK1 to suppress UV radiation-induced skin cancer","volume":"7","author":"Yao","year":"2014","journal-title":"Cancer Prev. Res. (Phila)."},{"issue":"22","key":"10.1016\/j.bcp.2019.06.014_b0140","doi-asserted-by":"crossref","first-page":"35761","DOI":"10.18632\/oncotarget.16204","article-title":"Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase","volume":"8","author":"Kosnopfel","year":"2017","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.bcp.2019.06.014_b0145","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1096\/fj.09-151290","article-title":"RSK2 mediates NF-{kappa}B activity through the phosphorylation of IkappaBalpha in the TNF-R1 pathway","volume":"24","author":"Peng","year":"2010","journal-title":"FASEB J."},{"issue":"76","key":"10.1016\/j.bcp.2019.06.014_b0150","doi-asserted-by":"crossref","first-page":"34200","DOI":"10.18632\/oncotarget.24409","article-title":"Carnosol suppresses patient-derived gastric tumor growth by targeting RSK2","volume":"9","author":"Wang","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.bcp.2019.06.014_b0155","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s13046-018-0897-x","article-title":"Vitexin compound 1, a novel extraction from a Chinese herb, suppresses melanoma cell growth through DNA damage by increasing ROS levels","volume":"37","author":"Liu","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.bcp.2019.06.014_b0160","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3889\/oamjms.2018.071","article-title":"The silent killer","volume":"6","author":"Tchernev","year":"2018","journal-title":"Open Access Maced J Med Sci."},{"issue":"3","key":"10.1016\/j.bcp.2019.06.014_b0165","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.steroids.2009.12.010","article-title":"RSK in tumorigenesis: connections to steroid signaling","volume":"75","author":"Eisinger-Mathason","year":"2010","journal-title":"Steroids"},{"issue":"20","key":"10.1016\/j.bcp.2019.06.014_b0170","doi-asserted-by":"crossref","first-page":"6099","DOI":"10.1158\/0008-5472.CAN-13-1087","article-title":"RSK isoforms in cancer cell invasion and metastasis","volume":"73","author":"Sulzmaier","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2019.06.014_b0175","doi-asserted-by":"crossref","DOI":"10.1038\/s41418-017-0055-6","article-title":"beta-Trcp ubiquitin ligase and RSK2 kinase-mediated degradation of FOXN2 promotes tumorigenesis and radioresistance in lung cancer","author":"Ma","year":"2018","journal-title":"Cell Death Differ."},{"issue":"8","key":"10.1016\/j.bcp.2019.06.014_b0180","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1158\/0008-5472.CAN-17-2063","article-title":"ERalpha-mediated nuclear sequestration of RSK2 Is required for ER(+) breast cancer tumorigenesis","volume":"78","author":"Ludwik","year":"2018","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.bcp.2019.06.014_b0185","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1158\/1535-7163.MCT-12-0605","article-title":"RSK2(Ser227) at N-terminal kinase domain is a potential therapeutic target for multiple myeloma","volume":"11","author":"Shimura","year":"2012","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.bcp.2019.06.014_b0190","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1471-4159.2011.07423.x","article-title":"Altered ERK\/MAPK signaling in the hippocampus of the mrsk2_KO mouse model of Coffin-Lowry syndrome","volume":"119","author":"Schneider","year":"2011","journal-title":"J. Neurochem."},{"issue":"1","key":"10.1016\/j.bcp.2019.06.014_b0195","doi-asserted-by":"crossref","first-page":"15726","DOI":"10.1038\/s41598-018-33879-w","article-title":"Fisetin targets YB-1\/RSK axis independent of its effect on ERK signaling: insights from in vitro and in vivo melanoma models","volume":"8","author":"Sechi","year":"2018","journal-title":"Sci. Rep."},{"issue":"33","key":"10.1016\/j.bcp.2019.06.014_b0200","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1021\/bi300620c","article-title":"Insights into the inhibition of the p90 ribosomal S6 kinase (RSK) by the flavonol glycoside SL0101 from the 1.5 A crystal structure of the N-terminal domain of RSK2 with bound inhibitor","volume":"51","author":"Utepbergenov","year":"2012","journal-title":"Biochemistry"},{"issue":"17","key":"10.1016\/j.bcp.2019.06.014_b0205","doi-asserted-by":"crossref","first-page":"6034","DOI":"10.1016\/j.bmc.2006.05.009","article-title":"Influence of rhamnose substituents on the potency of SL0101, an inhibitor of the Ser\/Thr kinase, RSK","volume":"14","author":"Smith","year":"2006","journal-title":"Bioorg Med Chem."},{"issue":"8","key":"10.1016\/j.bcp.2019.06.014_b0210","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.cellsig.2015.04.004","article-title":"Two widely used RSK inhibitors, BI-D1870 and SL0101, alter mTORC1 signaling in a RSK-independent manner","volume":"27","author":"Roffe","year":"2015","journal-title":"Cell. Signal."},{"issue":"1","key":"10.1016\/j.bcp.2019.06.014_b0215","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1042\/BJ20061088","article-title":"BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo","volume":"401","author":"Sapkota","year":"2007","journal-title":"Biochem. J."},{"issue":"3","key":"10.1016\/j.bcp.2019.06.014_b0220","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nchembio859","article-title":"A clickable inhibitor reveals context-dependent autoactivation of p90 RSK","volume":"3","author":"Cohen","year":"2007","journal-title":"Nat. Chem. Biol."},{"issue":"6","key":"10.1016\/j.bcp.2019.06.014_b0225","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/jcp.24858","article-title":"Protein kinase C inhibitor, GF109203X attenuates osteoclastogenesis, bone resorption and RANKL-induced NF-kappaB and NFAT activity","volume":"230","author":"Yao","year":"2015","journal-title":"J. Cell. Physiol."},{"issue":"2","key":"10.1016\/j.bcp.2019.06.014_b0230","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.neulet.2009.03.012","article-title":"The PKC inhibitor Ro31-8220 blocks acute amphetamine-induced dopamine overflow in the nucleus accumbens","volume":"455","author":"Loweth","year":"2009","journal-title":"Neurosci. Lett."},{"issue":"4","key":"10.1016\/j.bcp.2019.06.014_b0235","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nrclinonc.2016.183","article-title":"Activating autophagy to potentiate immunogenic chemotherapy and radiation therapy","volume":"14","author":"Galluzzi","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.bcp.2019.06.014_b0240","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.4161\/auto.7.10.16490","article-title":"Cleaving Beclin 1 to suppress autophagy in chemotherapy-induced apoptosis","volume":"7","author":"Li","year":"2011","journal-title":"Autophagy"},{"issue":"22","key":"10.1016\/j.bcp.2019.06.014_b0245","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1101\/gad.1599207","article-title":"Autophagy: process and function","volume":"21","author":"Mizushima","year":"2007","journal-title":"Genes Dev."},{"issue":"7","key":"10.1016\/j.bcp.2019.06.014_b0250","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.4161\/auto.28679","article-title":"Autophagy promotes resistance to photodynamic therapy-induced apoptosis selectively in colorectal cancer stem-like cells","volume":"10","author":"Wei","year":"2014","journal-title":"Autophagy."},{"key":"10.1016\/j.bcp.2019.06.014_b0255","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13046-016-0303-5","article-title":"Targeting autophagy to sensitive glioma to temozolomide treatment","volume":"35","author":"Yan","year":"2016","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.bcp.2019.06.014_b0260","doi-asserted-by":"crossref","first-page":"372","DOI":"10.4161\/auto.27163","article-title":"Autophagy suppresses melanoma tumorigenesis by inducing senescence","volume":"10","author":"Liu","year":"2014","journal-title":"Autophagy"},{"issue":"4","key":"10.1016\/j.bcp.2019.06.014_b0265","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1159\/000481971","article-title":"Inhibiting ROS-TFEB-Dependent Autophagy Enhances Salidroside-Induced Apoptosis in Human Chondrosarcoma Cells","volume":"43","author":"Zeng","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"issue":"11","key":"10.1016\/j.bcp.2019.06.014_b0270","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1002\/jcp.25785","article-title":"Crosstalk of autophagy and apoptosis: involvement of the dual role of autophagy under ER stress","volume":"232","author":"Song","year":"2017","journal-title":"J. Cell. Physiol."},{"issue":"32","key":"10.1016\/j.bcp.2019.06.014_b0275","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.1038\/sj.onc.1209421","article-title":"Epidermal growth factor and serum activate distinct pathways to inhibit the BH3 only protein BAD in prostate carcinoma LNCaP cells","volume":"25","author":"Chao","year":"2006","journal-title":"Oncogene"}],"updated-by":[{"DOI":"10.1016\/j.bcp.2020.114372","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000}}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219302333?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219302333?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:04:50Z","timestamp":1757768690000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295219302333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":55,"alternative-id":["S0006295219302333"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2019.06.014","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.bcp.2020.114372","asserted-by":"object"}]},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CX-F9, a novel RSK2 inhibitor, suppresses cutaneous melanoma cells proliferation and metastasis through regulating autophagy","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2019.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}